

# Melvin T Chin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7168035/publications.pdf>

Version: 2024-02-01

22  
papers

318  
citations

1170033

9  
h-index

939365

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

749  
citing authors

#	ARTICLE	IF	CITATIONS
1	What does co-design mean for Australia's diverse clinical workforce?. Australian Health Review, 2022, 46, 60-61.	0.5	4
2	Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma. Internal Medicine Journal, 2022, 52, 1103-1104.	0.5	0
3	Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice. Public Health Research and Practice, 2021, 31, .	0.7	5
4	Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology, 2021, 5, 561-568.	1.5	1
5	Codesigning consumer engagement strategies with ethnic minority consumers in Australian cancer services: the CanEngage Project protocol. BMJ Open, 2021, 11, e048389.	0.8	8
6	Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial. BMC Cancer, 2020, 20, 342.	1.1	1
7	Patient, general practitioner and oncologist views regarding long-term cancer shared care. Family Practice, 2018, 35, 323-329.	0.8	34
8	Using behaviour change and implementation science to address low referral rates in oncology. BMC Health Services Research, 2018, 18, 904.	0.9	22
9	The plot thickens: Archetypal narrative structure in the melanoma patient journey. Cogent Medicine, 2018, 5, 1484053.	0.7	1
10	Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy. Kidney and Blood Pressure Research, 2017, 42, 62-75.	0.9	18
11	Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report. BMC Research Notes, 2016, 9, 386.	0.6	6
12	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. Oncologist, 2016, 21, 618-625.	1.9	12
13	Achieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: a study protocol. BMC Health Services Research, 2016, 16, 89.	0.9	9
14	Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer. Oncology and Therapy, 2016, 4, 103-116.	1.0	5
15	Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment. Melanoma Research, 2014, 24, 408-412.	0.6	7
16	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2014, 20, 4449-4458.	3.2	56
17	Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation. BMC Research Notes, 2014, 7, 505.	0.6	11
18	Use of neostigmine in capecitabine-induced paralytic ileus. Tumori, 2013, 99, e225-e228.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Use of neostigmine in capecitabine-induced paralytic ileus. <i>Tumori</i> , 2013, 99, e225-8.	0.6	1
20	Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 597-605.	1.1	64
21	Rationale for treatment durations of targeted cancer agents. <i>Lancet Oncology, The</i> , 2010, 11, 1113-1115.	5.1	3
22	Primary pancreatic lymphoma “ pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. <i>BMC Cancer</i> , 2006, 6, 117.	1.1	49